DYNAMIC CHANGES IN O-GLCNACYLATION REGULATE OSTEOCLAST DIFFERENTIATION AND BONE LOSS IN ARTHRITIS (2021) Chen CW, Li YN, Trinh MT, Honglin Z, Matei AE, Ding X, Tran Manh C, et al. Conference contribution ANTI-S100A4 MONOCLONAL ANTIBODY TREATMENT AMELIORATES SKIN FIBROSIS IN INFLAMMATORY AND NON-INFLAMMATORY PRE-CLINICAL MODELS OF SYSTEMIC SCLEROSIS (2021) Tomcik M, Trinh MT, Trinh-Minh T, Tran Manh C, Storkanova H, Storkanova L, Senolt L, et al. Conference contribution ELDERLY PATIENTS ARE NOT AT INCREASED RISK OF SERIOUS INFECTIONS WHEN RECEIVING BDMARDS OR JAK INHIBITORS COMPARED TO CSDMARD TREATMENT (2021) Strangfeld A, Manger B, Worsch M, Schmeiser T, Zink A, Schaefer M Conference contribution EFFECTS OF THE AUTOTAXIN INHIBITOR ZIRITAXESTAT ON SKIN AND LUNG FIBROSIS IN A MURINE GRAFT-VERSUS-HOST DISEASE MODEL OF SYSTEMIC SCLEROSIS (2021) Zhang Y, Summa L, Heckmann B, Distler J Conference contribution SPATIOTEMPORAL DYNAMICS OF BONE LOSS BEFORE AND AFTER THE ONSET OF RHEUMATOID ARTHRITIS (2021) Tascilar K, Simon D, Liphardt AM, Meinderink T, Bayat S, Rech J, Hueber A, et al. Conference contribution INACTIVATION OF ALDEHYDE DEHYDROGENASE 3A2 INHIBITS FIBROBLAST ACTIVATION AND TISSUE FIBROSIS (2021) Xu X, Li YN, Chen CW, Trinh-Minh T, Schett G, Distler J Conference contribution 68GA-FAPI-04 PET/CT STUDY EXTENSION FOR THE ASSESSMENT OF FIBROBLAST ACTIVATION AND RISK EVALUATION IN SYSTEMIC SCLEROSIS-RELATED INTERSTITIAL LUNG DISEASE (2021) Bergmann C, Distler J, Treutlein C, Tascilar K, Müller A, Atzinger A, Matei AE, et al. Conference contribution EFFECTIVENESS AND SAFETY OF TOCILIZUMAB IN PATIENTS WITH SYSTEMIC SCLEROSIS: A PROPENSITY SCORE CONTROL MATCHED OBSERVATIONAL STUDY OF THE EUSTAR COHORT (2021) Kuster S, Jordan S, Elhai MD, Held U, Steigmiller K, Bruni C, Iannone F, et al. Conference contribution LONG-TERM OUTCOME OF SSC ASSOCIATED ILD: IMPROVED SURVIVAL IN PPI TREATED PATIENTS (2021) Kreuter M, Bonella F, Kathrin K, Henes J, Siegert E, Riemekasten G, Blank N, et al. Conference contribution PATIENT PREFERENCES, TRADE-OFFS AND ACCEPTABLE RISKS IN THE TREATMENT OF SYSTEMIC SCLEROSIS-ASSOCIATED INTERSTITIAL LUNG DISEASE: A STEP TOWARDS SHARED DECISION-MAKING (2021) Bruni C, Heidenreich S, Duenas A, Hoffmann-Vold AM, Gabrielli A, Allanore Y, Chatelus E, et al. Conference contribution